KRSA today
$37.56+$2.11 (+5.95%)close Nov 20, 2026Trend
DailyNeutral
4 hourAscending Triangle
1 hourStrong Bullish
15 minStrong Bullish
5 minSymmetric Triangle
Key levels
Support$35.34
Support$32.98
Latest news & SEC filings
AnalystWells Fargo starts Korsana Biosciences coverage with Overweight rating and $44 price target
EarningsKorsana Biosciences Posts Q3 2026 Results, Issues Update
EarningsKorsana Biosciences posts wider quarterly loss than analysts expected
All KRSA news →About Korsana Biosciences
Korsana Biosciences is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders. Its lead program, CYC-126, combines two generic intravenous anesthetics with a personalized delivery and brain-monitoring system for treatment-resistant depression, intended for use in hospital settings. The company also holds legacy soluble guanylate cyclase stimulator assets, including praliciguat, which is licensed to Akebia for focal segmental glomerulosclerosis, and olinciguat, for which it seeks licensing partners.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
Korsana Biosciences, Inc. (KRSA)
What Is the Price Target for KRSA?
SEPT Low Target
$43.00
SEPT Mid Target
$49.50
SEPT High Target
$70.00
Analyst Consensus
$49.50
Is KRSA a Buy or Sell Right Now?
Thesis
- •Revenue growing 3.7% YoY with ACCELERATING trend — accelerating momentum.
Test your own strategy on KRSA
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on KRSA with SEPT’s own market data.
Start Free Trial →Is KRSA Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$37.85
15
Moat Score
NONE
1/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with KRSA?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →KRSA Growth Story
Revenue YoY
3.7%
3yr Revenue CAGR
-19.3%
EPS Growth YoY
8.26%
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for KRSA
PREVIEWRecent off-exchange (dark pool) prints for KRSA: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:14:56 | $36.55 | 1,000 | $$37K | SELL |
| 18:46:41 | $37.11 | 1,400 | $$52K | MIDPOINT |
| 18:36:53 | $37.11 | 2,101 | $$78K | BUY |
| 16:33:24 | $37.85 | 11,500 | $$435K | SELL |
| 16:19:59 | $37.62 | 1,143 | $$43K | SELL |
5 dark pool trades shown · $$645K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Korsana Biosciences, Inc. (KRSA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Your strategy, tested before real money.
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →KRSA — frequently asked questions
What is KRSA stock price today?
Korsana Biosciences, Inc. (KRSA) is at $37.56, up 5.95% (+$2.11) at the Nov 20, 2026 close.
Why is KRSA stock moving today?
Latest KRSA news — Nov 13, 2026: Wells Fargo starts Korsana Biosciences coverage with Overweight rating and $44 price target · Nov 5, 2026: Korsana Biosciences Posts Q3 2026 Results, Issues Update
What is the KRSA price target?
The average analyst price target for KRSA is $49.50, ranging from $43 to $70, based on 4 analysts. Latest: Wedbush initiates on Oct 5, 2026.
What do analysts rate KRSA?
Analyst ratings for KRSA: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did KRSA beat earnings?
KRSA last reported on Nov 5, 2026: EPS -$3.19 vs -$0.85 expected — a miss of 275.3%.
What are KRSA support and resistance levels?
Support: $35.34, $32.98, $30.45.
What are insiders doing with KRSA?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on KRSA?
Nov 13, 2026: Wells Fargo starts Korsana Biosciences coverage with Overweight rating and $44 price target · Nov 5, 2026: Korsana Biosciences Posts Q3 2026 Results, Issues Update · Nov 5, 2026: Korsana Biosciences posts wider quarterly loss than analysts expected